Skip to main content
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.

1cP-MiPLA

1cP-MiPLA molecule structure1cP-MiPLA molecule structure
1-Cyclopropionyl-N-methyl-N-isopropyllysergamide
1cP-MIPLA, Lamide (parent compound)
Psychoactive Class
Psychedelic
Chemical Class
Lysergamide

1cP-MiPLA is a semisynthetic psychedelic of the lysergamide class that first emerged as a novel designer drug around 2020.citation needed It is a structural analog of MiPLA and is suspected to act as a prodrug for that compound, though insufficient data currently exists to confirm this relationship. As a research chemical with limited documented human use, its safety profile and pharmacological properties remain poorly characterized.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~50 µg
Light100-150 µg
Moderate150-200 µg
Strong200-250 µg
Heavy300+ µg

The spacing between threshold and light dose ranges is unusually wide, reflecting the scarcity of reliable dosing data for this recently emerged compound.

Duration

Onset20-40 minutes
Come Up45-90 minutes
Peak1-2 hours
Offset1-2 hours
Total4-6 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

1cP-MiPLA is believed to act as a prodrug for MiPLA, and its subjective effects are correspondingly reported to closely mirror those of its parent compound. The experience is that of a classic lysergamide psychedelic in the vein of LSD, though it is generally described as gentler, shorter-lasting, and less mentally demanding than LSD itself. Formal documentation of this compound remains minimal, and its effect profile is inferred largely from user reports and its relationship to MiPLA.

Physical

The body load is generally described as light, consisting primarily of mild stimulation alongside standard serotonergic psychedelic signs such as pupil dilation.

Pupil dilation

Cognitive

The headspace is often characterized as relatively clear and easygoing, with euphoria and an altered sense of time, and with less of the anxiety and cognitive intensity associated with LSD.

EuphoriaTime distortion

Visual

Visual effects are characteristic of lysergamide psychedelics but are typically milder than those of LSD at equivalent doses.

Color enhancement

Distortions

See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Morr(MO)
pink2 → green1
Ehrlich(EH)
No reaction
No reaction
Hofmann(HM)
No reaction
No reaction
Powered by PROtestkit.eu

Pharmacology

Pharmacodynamics

Direct receptor-binding and functional-activity data have not been reported for 1cP-MiPLA. The available primary study identified the substance in sheet products but did not assess its biological activity.1

Pharmacokinetics

No substance-specific metabolic pathway has been reported for 1cP-MiPLA.citation needed Conversion to MiPLA remains a hypothesis by analogy with other N1-acyl lysergamides: conversion of 1cP-LSD to LSD has been demonstrated in human serum, but conversion of 1cP-MiPLA to MiPLA has not.

Metabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

Lithium

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

Tramadol

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

AmphetaminesCannabisCocaineDiphenhydramineMephedronePregabalin
Powered by TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
Tolerance to the effects of 1cP-MiPLA develops almost immediately following ingestion, consistent with the rapid tolerance pattern observed with other lysergamide psychedelics.
Baseline Reset
Complete return to baseline tolerance typically requires around 14 days of abstinence from 1cP-MiPLA and other serotonergic psychedelics.
Half Tolerance
Approximately 5-7 days after use, tolerance is estimated to decrease to roughly half of its peak level.
Cross Tolerance

Serotonergic psychedelics (LSD, psilocybin, mescaline, DMT), Other lysergamides

Harm Potential

Addiction & Dependence

Psychological

Extremely Low

Assumed to be non-habit-forming based on its similarity to LSDcitation needed; the desire to use may actually decrease with repeated administration. No formal studies have been conducted.

Physical

Extremely Low

No evidence of physical dependence potential. Like LSD, 1cP-MiPLA is not associated with withdrawal symptoms or compulsive physical need for the substance.citation needed

Psychosis Risk

May act as a potential trigger for psychotic episodes in individuals with underlying psychiatric conditions or family history of mental illness.citation needed Adverse psychological reactions including delusions become more likely at higher doses, though severe psychotic episodes requiring medical attention are uncommon with this substance alone.

Seizure Risk

Seizures are reported rarely and are thought to mainly pose a risk in those who are genetically predisposedcitation needed, particularly when accompanied by physically taxing conditions such as dehydration, fatigue, or undernourishment. Risk is extrapolated from seizures reported following LSD use.

History & Culture

1cP-MiPLA is a novel synthetic lysergamide that first emerged on online research chemical markets around 2020.citation needed The compound's origins remain somewhat unclear, with unverified reports attributing its initial synthesis to either Skyler Ulrich or a chemist or group operating under the…

Legality

By Country

Illegal3
Austria flagAustriaIllegal (analog/blanket ban)
Germany flagGermanyIllegal
Russia flagRussiaSchedule I
Controlled / restricted1
Switzerland flagSwitzerlandControlled (Verzeichnis E)
Not scheduled1
United States flagUnited StatesUnscheduled

References

Source Pages

  1. Isomer Design (TiHKAL/PiHKAL)
  2. PsychonautWiki
  3. TripSit: Drug Combinations Chart
  4. Wikipedia

Citations

  1. Rie Tanaka, Maiko Kawamura, Sakumi Mizutani, & Ruri Kikura-Hanajiri. (2023). Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products. Forensic Toxicology, 41(2), 294–303. https://doi.org/10.1007/s11419-023-00661-112
  2. Neue-Psychoaktive-Substanzen-Verordnung (NPSV), consolidated official text, version 27 August 2026. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/GeltendeFassung/Bundesnormen/20007642/NPSV%2c%20Fassung%20vom%2027.08.2026.pdf1
  3. Neue-Psychoaktive-Substanzen-Verordnung, Anlage II (BGBl. II Nr. 106/2024). ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/Dokumente/Bundesnormen/NOR40261441/II_106_2024_Anlage_II.pdf1
  4. Neue-Psychoaktive-Substanzen-Gesetz (NPSG), consolidated official text, version 27 August 2026. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/GeltendeFassung/Bundesnormen/20007605/NPSG%2c%20Fassung%20vom%2027.08.2026.pdf1
  5. Anlage NpSG — Änderung vom 03.07.2021 (Einführung Stoffgruppe 5.2 Δ9,10-Ergolene), Verordnung vom 28.06.2021 (BGBl. I S. 2231). buzer.de (Gesetze-Änderungsdienst, Volltext mit BGBl.-Fundstellen) (n.d.). https://www.buzer.de/gesetz/12250/al149920-0.htm1
  6. § 3 NpSG — Unerlaubter Umgang mit neuen psychoaktiven Stoffen. Bundesministerium der Justiz (n.d.). https://www.gesetze-im-internet.de/npsg/__3.html1
  7. Постановление Правительства РФ от 30.06.1998 N 681 — Перечень наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации (ред. от 11.06.2025). Правительство Российской Федерации (n.d.). https://normativ.kontur.ru/document?moduleId=1&documentId=5031951
  8. Betäubungsmittelverzeichnisverordnung (BetmVV-EDI, SR 812.121.11), Anhang 5 Verzeichnis e, Ziff. 263 Lysergsäurederivate. Eidgenössisches Departement des Innern (EDI) / Bundesrecht (admin.ch) (n.d.). https://res.cloudinary.com/adminch/image/private/s--aGGgd8MH--/v1773719628/Bundespublikationen/812-121-11d.pdf12
  9. 21 U.S.C. § 813 — Treatment of controlled substance analogues (Federal Analogue Act). Cornell Law School, Legal Information Institute (U.S. Code) (n.d.). https://www.law.cornell.edu/uscode/text/21/8131

Further Reading

  1. Halberstadt A.L. et al. Pharmacological characterization of novel lysergamides including MiPLA. Neuropharmacology (2020)
  2. Tanaka R. et al. Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products. Forensic Science International (2023)
  3. TripReport.net substance overview: 1cP-MiPLA
  4. Wagmann L. et al. Analysis of LSD analogs (1cP-MiPLA, 1cP-LSD, etc.) in seized blotters. Forensic Toxicology (2021)

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Lyrea avatar
    Step 2 · First-pass review

    A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes8 human edits · latest

Times are UTCNewest first

24 July 2026

  1. Lyrea · Updated the article · also 1cP-AL-LAD, 1cP-LSD, 1P-ETH-LAD

14 July 2026

  1. Lyrea · Updated the article · also MiPLA

  2. Lyrea · Updated the article · also MiPLA

  3. Lyrea · Updated the article · also MiPLA

  4. Lyrea · Updated the article

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 1cP-MiPLA article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.